Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC Ltd : World’s leading Event Organizer

Conference Series LLC Ltd Conferences gaining more Readers and Visitors

Conference Series LLC Ltd Web Metrics at a Glance

  • 3000+ Global Events
  • 25 Million+ Visitors
  • 25000+ unique visitors per conference
  • 70000+ page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Vaccines and Immunology 2020

Welcome Message

 

Organizing Committee invites all the participants from all across the globe to attend 4 Euro

Global Summit and Expo on Vaccines & Vaccination

on December May 18-19, 2020 in Osaka, Japan which includes prompt keynote presentations, poster presentations, oral talks, and exhibitions.

 Vaccines World 2020 suggests that to unite the Professors, researchers, business mammoths, and technocrats to give a global gathering to the spread of unique research, new thoughts and viable improvement and find progresses within the field of immunizing agent, Vaccines and Vaccination, administration and instruction in connection to VaccineImmunization and Vaccination and additionally an expansiveness of different subjects.

This meeting makes a stage for Policy-creators, Scientists, agents and leaders in immunizing agent, protection and Vaccination to show their most up-to-date analysis and conclude regarding all the imperative advancements in VaccineImmunization and Vaccination. Real subjects talked about are Latest developed vaccinesProduction and effectiveness of vaccines,Types of vaccines, Veterinary vaccinesPediatric vaccinesVaccines against drugs, Vaccines and autism,Vaccines for unconventional diseases, and plant-derived vaccines, Vaccines safety and efficiencyCurrent research and future challenges in vaccines, Society and cultural aspects of vaccines.

Objective:
Vaccines World is a platform to achieve the prevailing gaps in the transformation of this multidisciplinary science of hope, to serve promptly with solutions to all in the need.  will have anticipated participation of 120+ delegates across the world to discuss the purpose of the conference.

Vaccines World 2020 unites people who have an enthusiasm for various fields of Vaccine and Vaccination. Target Audience will be workforce from both mechanical and scholastic fields which incorporate; Professors, researchers, CEOs, Directors, Vice Presidents, Co-executive, Biotechnologists, Managing Directors, Industry Safety Officers, Environmental and Plant Scientists, Doctorates, Professors, Post Doctorate Fellows, Vendors of Consumer Products/Managers, Pharmaceutical Scientists, Students from the related fields.

Why to Attend???

Vaccines World 2020 gives a worldwide stage to trading thoughts and makes us overhauled about the most recent advancements in the field of Vaccine, Immunization and Vaccination. The chance to go to the presentations conveyed by Eminent Scientists from everywhere throughout the world.

Target Audience:

•Eminent personalities
•Directors/Managers
•Head of Departmental
•Presidents/Vice-presidents
•CEO's of biotech companies
•Professors, Associate and Assistant professors
• Doctors
• Research Scholars and students from the related fields
• Other experts in Vaccines

Registration Benefits:

Only Registration Includes
01. Access to all Sessions
02. Handbook & Conference Kit
03. Certificate Accreditation by the International Organizing Committee Members (IOCM)
04. Abstracts will be published in the conference and respective international journal
05. Each registrant will get 50% abatement on manuscript publication fees
06. Ask an Expert Forums (One to One Pre-Scheduled meeting on interest and availability)
07. 10% abatement on registration fees for the next annual conference
08. 10% abatement on the membership of the International conference
09. Coffee breaks (refreshments and snacks) during the conference
10. Lunch during the conference
11. Wi-Fi

Package A: Above 11 features including the following...

12. Breakfast during the Conference
13. 02 Night’s accommodation (i.e. December 8th & 9th) in the deluxe single/double room at the conference venue

Package B: Above 13 features including the following...

14. 1 Night extra accommodation i.e. December 10th (total 3 nights)
Discounts are available on Group Registrations
20% discount available on the group of 10+ members.

About Vaccines World 2020


Vaccines World 2020 propose a gregarious invite to all the Directors, Deans, Heads, Scientists, Professors, Speakers, Research professionals and especially including attendees, speakers, exhibitors and sponsors from all over the world to involve in this prestigious event named with its series as “40th Euro Global Summit and Expo on Vaccines & Vaccination" that is going to be held on May-18-19, 2020 in Osaka, Japan  known for promoting scientific temperament and has been performing very well in Business and Management and is a perfect platform for our readers. The main motto is to make information on science and technology. It is a specialized medical and science publisher that operates in collaboration with the association and societies.


Vaccines World 2020 The firm has been engineered on the bottom of honored educational and analysis establishments as well as the school of Audiologists and Speech-Language Pathologists of Ontario (CASLPO), The Association of Public Safety Communications officers of North American nation (APCO), The Canadian tube Access Association (CVAA), and therefore the Canadian Society of medical specialty (CSIM).

 

 

About Conference


On behalf of the Advisory Committee we take great pleasure in welcoming academic scientists, researchers, research scholars, students and experts of application fields to Osaka, Japan for the 40th Euro Global Summit and Expo on Vaccines & Vaccination to foster the advancement in the field by contributing with your expertise to what promises to be a very comprehensive and exciting meeting in the fascinating location of Frankfurt.

40th Euro Global Summit and Expo on Vaccines & Vaccination (Euro Vaccines 2020), is going to be held during May 18-19, 2020 in Osaka, Japan. The vaccines conferences are attracting global participant’s intent on sharing, exchanging and exploring new avenues of Vaccines and Immunology Research & Development. The event will have plenary speakers, established Keynote speakers, young researcher’s presentations and poster presentations. In addition, there will be poster presentations along with workshops and special sessions would be interested in audience.

The aim of the Vaccines Conference is to promote quality research and real-world impact in an atmosphere of true international cooperation between scientists by bringing together the world class researchers, International Communities and Industrial heads to discuss the latest developments and innovations in the fields of Vaccines and Immunology.http://vaccinesworld.insightconferences.com

We sincerely hope that Euro Vaccines 2020 serves as an international platform for meeting researchers from around the world, widen professional contact and create new opportunities, including establishing new collaborations.

We are looking forward to seeing you at Euro Vaccines 2020 in Osaka, Japan.

 

 

Session/Tracks

Vaccines and  Immunization

THEME:

Progress and Novel Strategies in vaccines and Immunology Research.

Session\Tracks

Track 1: Vaccines

Vaccines play an important role in keeping us healthy. They protect us from serious and sometimes deadly diseases like haemophilus influenza type b (Hib) and measles.it is made from very small amounts of weak or dead germs that can cause diseases for example, viruses, bacteria, or toxins. It prepares your body to fight the disease faster and more effectively so you won’t get sick. Challenge in vaccine development consists in devising a vaccine strong enough to ward off infection without making the individual seriously ill. To that end, researchers have derived different types of vaccines.

Track 2: Types of Vaccines

 Depending upon the strategies used to reduce the risk of illness caused by a vaccine, while retaining their ability to induce a beneficial immune response they are classified into various types. The Human vaccines against viruses were made using weaker or attenuated viruses whereas a small pox vaccine is made of cowpox, a poxvirus similar enough to smallpox virus to create immunity. Several different processes are involved in Vaccine production based on which they are classified into different types. 

  • Live attenuated vaccines
  • Inactivated/ Killed vaccines
  • Toxoid
  • Subunit/ Conjugate

Track 3: Paediatric Vaccines

Immunization against diseases such as Polio, Tetanus, Diphtheria, and Pertussis saves the lives of approximately three million children each year. Immunization or Vaccination also prevents many more millions from suffering debilitating illness and lifelong disability. Globally, approximately 132 million babies need to be fully immunized each year. In order to meet this need, immunization systems must have adequate resources, trained and motivated staff, and ample vaccines and syringe supplies. Today, children in the United States routinely get vaccines that protect them from more than a dozen diseases such as measles, polio, tetanus, diphtheria, and pertussis (whooping cough). ... For example, children don't receive measles vaccine until they are at least one year old.

Track 4: HIV Vaccines                                                                                                              

The most vital achievements of the previous century included the development of vaccines to ensure against infections or infectious diseases: smallpox, polio, hepatitis, human papillomavirus (HPV), and even chickenpox. Be that as it may, one infection stays slippery to those looking to make an immunization to prepare for it: HIV. Getting immunized ahead of schedule, before sexual introduction, is additionally viable in keeping certain kinds of STIs. Vaccines are available to prevent human papillomavirus (HPV), hepatitis A and hepatitis B. Today, more people living with HIV than ever before have access to life-saving treatment with HIV medicines (called antiretroviral therapy or ART), which is good for their health. When people living with HIV achieve and maintain viral suppression by taking medication as prescribed, they can stay healthy for many years and greatly reduce their chance of transmitting HIV to their partners. In addition, others who are at high risk for HIV infection may have access to pre-exposure prophylaxis (PrEP), or ART being used to prevent HIV. Yet, unfortunately, in 2015, 39,513 people were diagnosed with HIV infection in the United States, and more than 2.1 million people became newly infected with HIV worldwide. To control and ultimately end HIV globally, we need a powerful array of HIV prevention tools that are widely accessible to all who would benefit from them.

Track 5: Veterinary Vaccines

The major goals of veterinary vaccines are to improve the health and welfare of companion animals, increase production of livestock in a cost-effective manner, and prevent animal-to-human transmission from both domestic animals and wildlife. These diverse aims have led to different approaches to the development of veterinary vaccines from crude but effective whole-pathogen preparations to molecularly defined subunit vaccines, genetically engineered organisms, vectored antigen formulations, and naked DNA injections. The final successful outcome of vaccine research and development is the generation of a product that will be available or sell in the marketplace or that will be used in the field to achieve desired outcomes. As detailed in this review, successful veterinary vaccines have been produced against viral, bacterial, protozoal, and multicellular pathogens, which in many ways have led the field in the application and adaptation of novel technologies

Track 6: Toxoid Vaccines

Toxoid immunizations are delivered utilizing a toxic substance (harm) that has been made safe anyway that moves a safe immuno response against the toxic substance. depend upon the toxic substance made by particular microorganisms (e.g. tetanus or diphtheria). The toxic substance assaults the circulatory framework and is, all things considered, accountable for the reactions of the illness. The protein-based toxic substance is rendered harmless and used as the antigen in the vaccination to bring out resistance.

  • Allergic reactions
  • Hypersensitivity
  • Biotherapeutics

Track 7: Tuberculosis Vaccines

Tuberculosis (TB) Vaccines are inoculations expected for the neutralizing activity of tuberculosis. Around three out of each 10,000 people who get the counter acting agent experience indications, (typically minor beside in to great degree immuno-debilitated individuals). While BCG immunization gives really successful protection to infant youngsters and energetic kids, its ampleness in adults is variable, running from 0% to 80%. A few variables have been considered as accountable for the evolving results. Interest for TB immunotherapy movement exists because the infection has advanced toward winding up continuously sedate safe.

  • Antituberculous Vaccine Development
  • Pulmonary Vaccines
  • Pre-infection TB Vaccine

Track 8: Animal and Plant derived Vaccines

Although, the concept of plant-based pharmaceuticals or vaccines motivates us to develop practicable commercial products using plant engineering, there are some difficulties in reaching the final goal: to manufacture an approved product. At present, the only plant-made vaccine approved by the United States Department of Agriculture is a Newcastle disease vaccine for poultry that is produced in suspension-cultured tobacco cells. The progress toward commercialization of plant-based vaccines takes much effort and time, but several candidate vaccines for use in humans and animals are in clinical trials. This review discusses plant engineering technologies and regulations relevant to the development of plant-based vaccines and provides an overview of human and animal vaccines currently under clinical trials.

Track 9: Fish and Poultry Vaccines

Vaccines developed for aquaculture have reduced antibiotic use in fish production. Currently, vaccines are available for some economically important bacterial and only few vaccines for viral diseases and no vaccine developed for fish parasites and fungus. Major limitations in fish vaccine developments are less understanding of fish immunology, many vaccines unlicensed, not cost effective (as these are expensive) and stressful on administration. Research are needed to review on the present status of fish vaccination for controlling fish diseases, and shows the needs and directions for future investigations.

Track 10: Travel and Edible Vaccines

Travel vaccines are used to provide protection or immune response against diseases endemic to the country of origin or of destination. They are intended to protect travellers and to prevent disease spread within and between countries. There is no single vaccination schedule that fits all travellers. Each schedule must be individualized according to the traveller’s previous immunizations, health status and risk factors, the countries to be visited, the type and duration of travel, and the amount of time available before departure. 

Edible vaccines hold great promise as a cost-effective, easy-to-administer, easy-to-store, fail-safe and sociocultural readily acceptable vaccine delivery system, especially for the poor developing countries. It involves introduction of selected desired genes into plants and then inducing these altered plants to manufacture the encoded proteins.

Track 11: DNA & Synthetic Vaccines

Scientists take many approaches to designing vaccines against a microbe. These choices are typically based on fundamental information about the microbe, such as how it infects cells and how the immune system responds to it, as well as practical considerations, such as regions of the world where the vaccine would be used. A DNA vaccine against a microbe would evoke a strong antibody response to the free-floating antigen secreted by cells, and the vaccine also would stimulate a strong cellular response or antibody formation against the microbial antigens displayed on cell surfaces. The DNA vaccine couldn’t cause the disease because it wouldn’t contain the microbe, just copies of a few of its genes. In addition, DNA vaccines are relatively easy and inexpensive to design and produce. 

Track 12:  Combination and Conjugate Vaccines

Increasingly, more diseases are becoming vaccine preventable, but maintaining community and provider acceptance demands that the number of injections doesn’t increase. Combination and conjugate vaccines represent an inevitable and important advance. This paper reviews the efficacy and safety of combination conjugate vaccines, including immunological mechanisms underlying interactions among vaccine epitopes, the role of immunological memory, and correlates of immunity. Specific attention is given to the experience with combination vaccines against each of Haemophilus influenzae type b, Streptococcus pneumoniae and Neisseria meningitidis. The implications of these findings for different communities are discussed, key areas for further research identified and implications for post-licensure monitoring addressed.

Track 13: Cancer Malaria & Tuberculosis Vaccines

Malaria continues to claim an estimated 2 to 3 million lives annually and to account for untold morbidity in the approximately 300 to 500 million people infected annually. Malaria is considered a re-emerging disease, due largely to the spread of drug-resistant parasite strains, decay of health-care infrastructure and difficulties in implementing and maintaining vector control programs in many developing countries. Four species of protozoan parasites cause malaria in humans: Plasmodium falciparum, P. vivax, P. malariae, and P. ovale. P. falciparum is responsible for the majority of deaths and most of the severe forms of disease, including cerebral malaria. 2 billion people latently infected with M. tuberculosis 5-10% infected people progress to disease 9 million new TB cases each year 1.5 million TB deaths each year Equivalent to 20 passenger aircraft crashes each day. TB is transmitted by adults with cavitatory disease HIV infected people carry greater burden of disease. Highest risk of progression from TB infection to active disease, and worst TB morbidity & mortality, compared to older children and adults.

Track 14: Bacterial Vaccines

Bacterial vaccines contain executed or constricted microbes that actuate the resistant framework. Antibodies are worked against that specific microorganisms form antibodies and avoids bacterial disease later. A case of a bacterial immunization is the Tuberculosis vaccine.

 

  • Diphtheria and tetanus toxoids usage in paediatrics
  • Inactivated bacterial vaccines
  • Innovative toxoid vaccine development
  • Live attenuated bacterial vaccinations
  • Maternal immunization

Track 15: Childhood and Maternal Vaccines

Vaccination is the best technique for preventing from irresistible diseases; far reaching invulnerability because of inoculation is to a great extent in charge of the overall annihilation of smallpox and the disposal of illnesses, for example, polio, measles, and lockjaw from a great part of the world. Maternal inoculation is a viable technique to forestall as well as limit the seriousness of irresistible illnesses in pregnant ladies and their new-born children.

 

 

  • Chickenpox vaccine
  • Diphtheria vaccines
  • Haemophilus influenza type b vaccines
  • Hepatitis A vaccines
  • Hepatitis B vaccines
  • Influenza vaccines
  • MMR vaccines
  • Pneumococcal Vaccine
  • Polio vaccines

Track 16: Protein based Vaccines

Hepatitis B vaccinations are made out of the hepatitis B disease surface antigen (HbsAg), a protein made by hepatitis B impurity or contamination . Earlier inoculation things were made using cleansed plasma of polluted individuals. This creation procedure has been supplanted by recombinant development that can convey HbsAg without requiring human plasma extending the security of the vaccination by banishing the peril from potential spoiling of human plasma.

  • Public health concerns in vaccination
  • Contraindications - Vaccines, vaccination
  • Vaccines formulation and technologies used in conjugated vaccines

Track 17: Zika Virus Vaccines

The Live-Attenuated vaccine is produced to the disease caused by Zika Virus. The monovalent (having a valance of 1)form of the antibody is outlined against Zika infection contamination. Zika Virus has a place with the Genus Flavivirus, or, in other words the Aedes mosquitos. The comprehension of flavivirus molecule structure, meaning of E dimers as the key antigenic target, and profound comprehension of balance systems help to build up the antibody.

  • Zika Virus Vaccines Clinical Trials
  • Zika Virus Vaccine Development
  • Zika Virus Vaccines Recent Research
  • Purified Inactivated Vaccine

Track 18: Giving Vaccination

Immunization is a routine procedure for healthy workers, but can be frightening for children and adults attending the session. There are many things a healthy worker can do to make an immunization experience a safe effective and positive one. This section focuses on techniques for injection preparation, the comfortable and safe positioning of children, and the safe disposal of materials.

 

  • Preparing to Vaccinate
  • Reconstituting Vaccines and Steps for Reconstitution
  • Making Vaccination Easier and more Comfortable
  • Good General Techniques
  • Positioning the Infant for Vaccination
  • Good Oral Administration Technique
  • Good Injection Technique
  • Intradermal (ID) Injection
  • Subcutaneous (SC) Injection in the Upper Arm
  • Intramuscular (IM) Injection in Infants

Track 19: Vaccines Production and Development

Vaccine development is an activity that focuses on a variety of technological initiatives and applied research, which upgrade and advance enhanced frameworks and practices for vaccine safety and production. In the previous year, the exceptional Ebola sickness flare-up aroused research and industry reaction and as we keep on scanning for arrangements, we should audit the exercises learned with the end goal to beat the flow challenges. The present framework for creating, testing, and directing immunizations created amid the twentieth century as the gatherings included institutionalized their methods and controls.

 

  • Egg-based vaccines
  • Mammalian cells-based vaccines
  • Production using plant, insect cells or bacteria cultures
  • Investigational vaccines manufacture
  • Clinical development of vaccines

Track 20: Immune Diseases

The immune system has developed a variety of approaches to controlling viral and bacterial infection, which range from direct killing of pathogen to elaborating cytokines that inhibit replication.Faculty and student efforts to define and characterize these opposing mechanisms will undoubtedly lead to improved treatment and immunization of infectious diseases ranging from AIDS and parasitic infections to sexually transmitted diseases and the common cold.

 

 

  • Scleroderma and Lupus
  • Autoimmune lymphoproliferative Syndrome
  • Type one diabetes and Vasculitis
  • Graves’ Disease
  • Rheumatoid Arthritis
  • Multiple Sclerosis
  • Pernicious Anaemia
  • Hyper-Immunoglobulin E Syndrome

Track 21: Immunoresearch and Immunotechnology

Immunology is worried about the utilization of immunological responses for the determination, avoidance, and treatment of various infections and infectious diseases. It is firmly identified with therapeutic and veterinary microbiology, the study of disease transmission, physiology and Pathophysiology, organic chemistry, and endocrinology. Immunology concentrates the antigenic creation of microorganisms, attributes of the safety procedures in different sorts of contaminations, and nonspecific types of Imperviousness to the causative operators of irresistible infections. Investigation of the immunological procedures and the immunological reproduction of the living being created by Non-infectious Antigens of the exogenous and endogenous starting point and the advancement of strategies for controlling unfavourably susceptible sicknesses are winding up noticeably progressively imperative articles, symposia, publications, and hypothetical expositions

  • Antibody Engineering & Technology
  • Novel Approaches & Technology Development
  • Nano-Immunotechnology
  • IgA Ligand
  • Affibody-Fusions
  • Immunological Assay
  • Transcriptomics & Immunodiagnostic
  • Antigen-Antibody Interactions

 

 

Market Analysis

40th Euro Global Summit and Expo on Vaccines & Vaccination Date & Venue: May 18-19, 2020 Osaka, Japan  Vaccines & Immunization conference welcomes attendees, presenters and exhibitors from all over the world to Osaka, Japan. We are delighted to invite you all to attend and register for the “40th  Global Summit and Expo on Vaccines & Vaccination” which is going to be held during May 18-19, 2020 Osaka, Japan  

 

The organizing committee is gearing up for an exciting and informative conference program including plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from all over the world. We invite you to join us at on 40th Euro Global Summit and Expo Vaccines &Vaccination, where you will be sure to have a meaningful experience with scholars from around the world. All members of the organizing committee look forward to meeting you in Osaka, Japan.

 

 

Importance & Scope:

The worldwide clinical immunology market is anticipated to achieve USD 5.77 Billion by 2021 from USD 3.35 Billion in 2016, developing at a CAGR of 11.5% from 2016 to 2021. Showcase development can be credited to variables, for example, the mechanical headways; rising rate of irresistible illnesses and developing flare-up of plagues; developing medicinal services consumption over the world; and expanding financing, inquire about gifts, and open private interests in the field of life science explores.

 

The irresistible immunology market is sectioned in light of sorts of infections into HIV, hepatitis, pneumonia, tuberculosis, jungle fever, provocative inside sicknesses and immune system ailments. Around 4, 00,000 passings are evaluated to be brought about by rotavirus disease. HBV influenced almost 1.4 million in the U.S. in 2011. The rising frequency of these irresistible illnesses makes an overall interest for immunological diagnostics and treatment. This recommends the market would encounter a development spurt sooner rather than later. Be that as it may, the absence of mechanical advancements and high cost related with treatment would unfavorably influence advertise development. The irresistible immunology market is sectioned in view of the sorts of items utilized for treatment, for example, indicative units, instruments and reagents. Demonstrative units hold the overwhelming offer because of their adequacy. Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientifics, Bio-Rad Laboratories and Dr. Reddy's Laboratories are the key players in the irresistible immunology showcase.

                                                                                                  

           

 

MARKET GROWTH AND ANALYSIS IN HEALTHCARE INDUSTRY

Vaccination plays a crucial role to maintain sustainable health of people across different countries; hence, they are employed in various regional disease-prevention strategies. The demand for vaccinations has increased over the last few years, owing to the increase in incidence of both viral and bacterial infectious diseases. Vaccinations are essentially administered to people of different age groups, which strengthen their immune system throughout lifetime and offers protection against different types of infectious diseases.

 

Global Vaccines Market was valued at $31,216 million in 2016, and is expected to reach $65,148 million in 2023, and register a CAGR of 10.9%, during the forecast period, 2017‐ 2023. Vaccine is a biological preparation that is administered to produce acquired immunity in patients. Administration of vaccines aids to enhance the immune response against a specific pathogen.

 

The global vaccines market is driven by the rise in prevalence of infectious diseases, as it is considered to be the best way to prevent such diseases. In addition, emerging vaccines (Zika vaccines, dengue vaccines, cancer vaccines, and others), production of technologically advanced vaccines, advancements in vaccine delivery devices, and increase in immunization programs supplement the market growth. However, longer timelines required to produce vaccines and high monetary inputs associated with the same restrict the market growth. Furthermore, high growth of vaccine production in emerging markets is expected to offer lucrative opportunities in the near future.

Commitment to the Immunological Research around the world

 

Why Osaka,Japan?

Osaka is the capital and largest city of Japan. It is the most famous city; it exerted a huge influence all over the world in its approximately 3000 years of existence. In 1989,

Rubella Epidemic

 In 1995, the NIP revised its vaccination policy, to now strongly recommend, but not make mandatory, the rubella vaccine for males and females, aged 12–90 months. On 4 subsequent occasions the government made temporary recommendation changes specific to different populations susceptible to rubella: for first- and second-year elementary school students, in 1995; for first-year elementary school students, in 1996–1999; for junior high school students without a history of rubella, in 2001–2003; and for unvaccinated individuals aged 16–24 years, in 2001–2003. From 2006 onward, measles and rubella vaccine (MR) has been given free-of-charge to children aged 1 y and 5–6 more

Due directly to these gaps in ‘herd’ immunization resulting from politicized transitions in vaccination policy by the government, there were outbreaks of rubella with 17,050 cases reported between the years of 2012 and 2014, and 45 cases of congenital rubella syndrome reported to the National Epidemiological Surveillance of Infectious Diseases from week 1, 2012 to week 40, 2014. Currently, the majority of recent rubella epidemic cases are occurring among adults aged 20–40. There still exist large populations susceptible to rubella in Japan.

 

Why to attend???

It will provide exposure to the possibilities in Vaccination. It will avail the more importance of vaccination. It will also provide insight to the noble inventions and techniques. It is very beneficial for the students, physicians, health care people, scientists, doctors, professors because it provides knowledge in the field. It also gives opportunities to the vaccination societies in Italy to showcase their knowledge and have face to face meetings with scientists increasing their business opportunities. It also gives opportunity to know about their market competitors.

 

Top Societies and Association around the World:

           European Respiratory Society

           Danish Cancer Society

           Brazilian Society of Immunizations

           European Society of Gene Therapy

           European Society for Immunodeficiency

           French Society of Immunology    

           European malaria Vaccine Initiative (EMVI)

Past Conference Report

 

 

Euro Vaccines 2019 Report

                                                                                                                                                         2nd International Conference on Vaccine Research hosted by Conference series LLC Ltd during June 14-16, 2018 at Geneva, Switzerland with a theme “Recent Advancements in Vaccination and Antibiotic Applications” and was a great success where eminent Keynote Speakers, Speakers, Delegates and Poster Presenters from various reputed companies and Universities made their resplendent presence and addressed the gathering.

European Vaccines 2019 witnessed an amalgamation of peerless speakers who enlightened the crowd with their knowledge and confabulated on various new-fangled topics related to the field of Vaccines and Therapeutics.

We would like to convey a great appreciation to following eminent people, honorable guests and Keynote speakers.

Gabriel Kristina Pedersen, Staten’s Serum Institute, Denmark

Carmen Alvarez-Dominguez, Institute de Investigation Marquees de Valdecilla, Spain

Frederic J Decamps, University Hospital of Reims, France

Randa S Hamada, Ministry of Public Health, Lebanon

Special thanks to our Honorable Moderator, Dr. Frederic J Decamps for his remarkable contribution towards smooth functioning at European Vaccines 2019 Conference.

Conference series LLC Ltd on behalf of the conference congratulates the Best Poster awardees for their outstanding performance and appreciates all the participants who put their efforts in presentations and sincerely wishes them success in future endeavors.

Conference series LLC Ltd would like to convey a warm gratitude to Chairs and Co-chairs who contributed effervescently for the smooth functioning of the event, Frederic J Deschamps, University Hospital of Reims, France and Chit Laa Pooh, Sunway University, Malaysia.

European Vaccines 2019 conference was a great success with the support of International multi professional steering committee and coordinated by Journal of Vaccines & VaccinationJournal of Clinical & Cellular Immunology and Immunize Research.

Our sincere thanks to Organizing Committee Members for their gracious presence, support and assistance towards European Vaccines 2019 conference and with the enormous feedback from the participants and supporters of European Vaccines 2019, Conference series LLC Ltd is glad to announce 40th Euro Global Summit and Expo on Vaccines & Vaccination on Vaccines Research, May 18-19, 2020, Osaka , Japan.

 

To Collaborate Scientific Professionals around the World

Conference Date May 18-19 2020,

For Sponsors & Exhibitors

sponsor@conferenceseries.com

Speaker Opportunity

Past Conference Report

Supported By

All accepted abstracts will be published in respective Conference Series LLC LTD International Journals.

Abstracts will be provided with Digital Object Identifier by